AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17904460 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal quality improvement intervention (audit and feedback, educational modules, teleconferences, academic detailing)
Number of subjects: 606
Study 17904460 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 606
Study 17904460 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of educational module
Number of subjects: 606
Study 17904460 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct physician contact by an academic detailer
Number of subjects: 606
Study 15379416 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 48
Study 15379416 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with hyperlipidemia
Number of subjects: 48
Study 15379416 — intervention group
Group type: COMPARATOR
Intervention: Non-obese controls
Number of subjects: 48
Study 16924985 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch and rinse adhesive systems (SBMP, OS, SB1, G)
Number of subjects: 70
Study 16924985 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive systems (PLP, X-III, iB)
Number of subjects: 70
Study 16924985 — intervention group
Group type: EXPERIMENTAL
Intervention: X-III (self-etch adhesive)
Number of subjects: 70
Study 16924985 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite lining under PLP adhesive
Number of subjects: 70
Study 10908001 — intervention group
Group type: EXPERIMENTAL
Intervention: manualized, cognitive‐behavioral outpatient treatment developed by the Matrix Center in Los Angeles
Number of subjects: 0
Study 10908001 — intervention group
Group type: COMPARATOR
Intervention: treatment approaches currently employed by the treatment sites
Number of subjects: 0
Study 8700338 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepartricin 150,000 U (40 mg) once in the evening for 60 days
Number of subjects: 25
Study 8700338 — intervention group
Group type: COMPARATOR
Intervention: Mepartricin 50,000 U (13 mg) t.d.s.
Number of subjects: 25
Study 1656828 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon
Number of subjects: 41
Study 1656828 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study 7058868 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 0
Study 7058868 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 0
Study 7058868 — intervention group
Group type: COMPARATOR
Intervention: Baseline treatments
Number of subjects: 0
Study 31657011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 38
Study 31657011 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic Therapy (ST)
Number of subjects: 38
Study 31657011 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ST vs CBT
Number of subjects: 38
Study 30791796 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention-Task Shifting (CTI-TS)
Number of subjects: 15
Study 29792215 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure (LAACS)
Number of subjects: 187
Study 29792215 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 187
Study 27184790 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention programs aimed at developing parents’ relationship and parenting skills.
Number of subjects: 53
Study 27184790 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal sensitivity and mother’s psychosocial stress.
Number of subjects: 53
Study 24957530 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18624
Study 24957530 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18624
Study 22295817 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture (treatment at Zhongwan (CV 12), Shangqu (KI 17) on healthy side, Huaroumen (ST 24) on affected side)
Number of subjects: 96
Study 22295817 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture (treatment at Jianyu (LI 15), Jianliao (TE 14), Jianzhen (SI 9) on affected side)
Number of subjects: 96
Study 21375021 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with dietary adjustments and aerobic exercise
Number of subjects: 61
Study 21375021 — intervention group
Group type: COMPARATOR
Intervention: Dietary adjustments and aerobic exercise
Number of subjects: 61
Study 18054551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation (1 night with ≤3 hours of sleep)
Number of subjects: 20
Study 18054551 — intervention group
Group type: COMPARATOR
Intervention: Sufficient sleep (3 days with ≥7 hours sleep/night)
Number of subjects: 20
Study 15631892 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 complement component
Number of subjects: 0
Study 15631892 — intervention group
Group type: EXPERIMENTAL
Intervention: C3 complement component
Number of subjects: 0
Study 15631892 — intervention group
Group type: EXPERIMENTAL
Intervention: C4 complement component
Number of subjects: 0
Study 15631892 — intervention group
Group type: EXPERIMENTAL
Intervention: C2 complement component
Number of subjects: 0
Study 15631892 — intervention group
Group type: COMPARATOR
Intervention: Total hemolytic activity of complement
Number of subjects: 0
Study 12128243 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 118
Study 12128243 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 118
Study 10092996 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants or omega‐3 fatty acids
Number of subjects: 0
Study 10092996 — intervention group
Group type: COMPARATOR
Intervention: Dietary intake of vegetables, vitamin C, beta‐carotene, folate, vitamin B12, omega‐3 fatty acids
Number of subjects: 0
Study 10092996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteinylglycine and vitamin B12
Number of subjects: 0
Study 10092996 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate in serum and blood
Number of subjects: 0
Study 10092996 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine
Number of subjects: 0
Study 7753957 — intervention group
Group type: COMPARATOR
Intervention: 0.0 mg nicotine polacrilex
Number of subjects: 21
Study 7753957 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg nicotine polacrilex
Number of subjects: 21
Study 7753957 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg nicotine polacrilex
Number of subjects: 21
Study 7753957 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg nicotine polacrilex
Number of subjects: 21
Study 7753957 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mg nicotine polacrilex
Number of subjects: 21
Study 2138590 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5%
Number of subjects: 0
Study 2138590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2138590 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5% vs Placebo
Number of subjects: 0
Study 31568675 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (Sustanon 250 mg)
Number of subjects: 18
Study 31568675 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 18
Study 29295808 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth intervention (website and mobile app with personalized convalescence plan, information about surgery and recovery, eConsult, activity tracker)
Number of subjects: 344
Study 29295808 — intervention group
Group type: EXPERIMENTAL
Intervention: eConsult function
Number of subjects: 344
Study 27966406 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention preceding infertility treatment
Number of subjects: 577
Study 27966406 — intervention group
Group type: COMPARATOR
Intervention: Prompt infertility treatment
Number of subjects: 577
Study 25189222 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided antimicrobial therapy
Number of subjects: 169
Study 25189222 — intervention group
Group type: COMPARATOR
Intervention: Standard antimicrobial therapy (control group)
Number of subjects: 169
Study 22277317 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES; Endeavor Sprint®)
Number of subjects: 160
Study 22277317 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES; Cypher®)
Number of subjects: 160
Study 20186574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print communication (TPC) + Telephone motivational interviewing (TMI)
Number of subjects: 266
Study 20186574 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 266
Study 17978254 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive Interview (EXIT) scores for employed group
Number of subjects: 213
Study 17978254 — intervention group
Group type: COMPARATOR
Intervention: Executive Interview (EXIT) scores for unemployed group
Number of subjects: 213
Study 17978254 — intervention group
Group type: COMPARATOR
Intervention: Lifetime psychiatric hospitalizations
Number of subjects: 213
Study 17978254 — intervention group
Group type: COMPARATOR
Intervention: Number of psychotropic medications prescribed
Number of subjects: 213
Study 17978254 — intervention group
Group type: COMPARATOR
Intervention: Executive functioning
Number of subjects: 213
Study 15805340 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg lidocaine
Number of subjects: 144
Study 15805340 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg lidocaine
Number of subjects: 144
Study 15805340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 11940288 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis combined with anticoagulant therapy
Number of subjects: 127
Study 11940288 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy alone
Number of subjects: 127
Study 11940288 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure anticoagulant therapy
Number of subjects: 127
Study 11940288 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (combined)
Number of subjects: 127
Study 11940288 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 127
Study 9871816 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 or 40 mg/day)
Number of subjects: 0
Study 9871816 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (50 or 100 mg/day)
Number of subjects: 0
Study 7620114 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxoprofen sodium 60 mg
Number of subjects: 5
Study 7620114 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 25 mg
Number of subjects: 5
Study 2231215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (n = 20)
Number of subjects: 178
Study 2231215 — intervention group
Group type: COMPARATOR
Intervention: Water placebo aerosol (n = 27)
Number of subjects: 178
Study 339995 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 100
Study 339995 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin and dapsone for six months
Number of subjects: 100
Study 339995 — intervention group
Group type: COMPARATOR
Intervention: Dapsone alone
Number of subjects: 100
Study 339995 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin alone
Number of subjects: 100
Study 31972765 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 60
Study 31972765 — intervention group
Group type: COMPARATOR
Intervention: Extended-release naltrexone
Number of subjects: 60
Study 31196505 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-motion protocol
Number of subjects: 58
Study 31196505 — intervention group
Group type: COMPARATOR
Intervention: Early-motion protocol
Number of subjects: 58
Study 31196505 — intervention group
Group type: COMPARATOR
Intervention: Noncompliant patients with shoulder immobilizer
Number of subjects: 58
Study 31196505 — intervention group
Group type: COMPARATOR
Intervention: Patients with torn rotator cuffs at 6 months
Number of subjects: 58
Study 31196505 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with greater improvements in QOL
Number of subjects: 58
Study 27530992 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation with standardized patients (SPs)
Number of subjects: 26
Study 27530992 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires
Number of subjects: 26
Study 25851052 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF 300 mg daily from 30-32 weeks of gestation until 1 month postpartum
Number of subjects: 118
Study 25851052 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF 300 mg daily
Number of subjects: 118
Study 25851052 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 118
Study 23303244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringers acetate (20 ml/kg)
Number of subjects: 10
Study 23303244 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4 (10 ml/kg)
Number of subjects: 10
Study 23303244 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Ringers acetate and hydroxyethyl starch
Number of subjects: 10
Study 23303244 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall bias across all pairs of measurements
Number of subjects: 10
Study 20400652 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol immediate-release (IR) 50 mg with paroxetine
Number of subjects: 10
Study 20400652 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol extended-release (ER) 100 mg with paroxetine
Number of subjects: 10
Study 20400652 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol immediate-release (IR) without paroxetine
Number of subjects: 10
Study 20400652 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol extended-release (ER) without paroxetine
Number of subjects: 10
Study 17997395 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Adaptation and Skills Training (FAST)
Number of subjects: 240
Study 17997395 — intervention group
Group type: COMPARATOR
Intervention: Attention-Control (AC)
Number of subjects: 240
Study 15984972 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoclips
Number of subjects: 47
Study 15984972 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 47
Study 12124862 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of activity
Number of subjects: 107
Study 10608721 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein A immunoadsorption (Immunosorba, Excorim AB, Lund, Sweden)
Number of subjects: 4
Study 10608721 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymectomy
Number of subjects: 4
Study 7576170 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline infusion (n = 35)
Number of subjects: 73
Study 7576170 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 38)
Number of subjects: 73
Study 1954070 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (1 microgram kg‐1)
Number of subjects: 9
Study 1954070 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (5 micrograms kg‐1)
Number of subjects: 9
Study 1954070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6168823 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 24
Study 6168823 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 24
Study 29660807 — intervention group
Group type: EXPERIMENTAL
Intervention: KingVision 'sniffing'
Number of subjects: 200
Study 29660807 — intervention group
Group type: EXPERIMENTAL
Intervention: KingVision neutral
Number of subjects: 200
Study 29660807 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC 'sniffing'
Number of subjects: 200
Study 29660807 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC neutral
Number of subjects: 200
Study 29660807 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 200
Study 28508838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-hepatic arterial weekly high-dose 5-fluorouracil (WHF)
Number of subjects: 91
Study 28508838 — intervention group
Group type: COMPARATOR
Intervention: Continuous venous infusion of 5-fluorouracil (CVI)
Number of subjects: 91
Study 26147923 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual Cup (MC)
Number of subjects: 40
Study 26147923 — intervention group
Group type: COMPARATOR
Intervention: Cervicovaginal Lavage (CVL)
Number of subjects: 40
Study 22804816 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium mucosal surfaces
Number of subjects: 19
Study 22804816 — intervention group
Group type: COMPARATOR
Intervention: Reinforced composite resin mucosal surfaces
Number of subjects: 19
Study 22804816 — intervention group
Group type: COMPARATOR
Intervention: Acrylic resin mucosal surfaces
Number of subjects: 19
Study 21370262 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg pramipexole
Number of subjects: 45
Study 21370262 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ropinirole
Number of subjects: 45
Study 21370262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 18639987 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity (median=1.65 kcal/kg/day expended from physical activity)
Number of subjects: 620
Study 18639987 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 620
Study 16631247 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg x 3) with mental stress
Number of subjects: 0
Study 16631247 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg x 3) with exercise
Number of subjects: 0
Study 16631247 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg x 3) after postexercise meal
Number of subjects: 0
Study 16631247 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated caffeine doses throughout the test day
Number of subjects: 0
Study 15476475 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 71
Study 15476475 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 71
Study 11174054 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg)
Number of subjects: 16
Study 11174054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11174054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 16
Study 11174054 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 16
Study 9022870 — intervention group
Group type: EXPERIMENTAL
Intervention: Current dieting for weight loss or weight maintenance
Number of subjects: 999
Study 9022870 — intervention group
Group type: EXPERIMENTAL
Intervention: Current dieters and those with an extensive history of dieting
Number of subjects: 999
Study 9022870 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight suppression
Number of subjects: 999
Study 8385975 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. magnesium sulphate 1 g h‐1 over 8 h
Number of subjects: 16
Study 8385975 — intervention group
Group type: COMPARATOR
Intervention: NaCl 18 mg h‐1 (control)
Number of subjects: 16
Study 3825543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily for 30 days (extended to 3 months for 3 patients)
Number of subjects: 20
Study 3825543 — intervention group
Group type: COMPARATOR
Intervention: Antacids 350 mmol daily for 30 days (extended to 3 months for 4 patients)
Number of subjects: 20
Study 28796989 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (NaP) solution
Number of subjects: 293
Study 28796989 — intervention group
Group type: EXPERIMENTAL
Intervention: NaP enema
Number of subjects: 293
Study 28796989 — intervention group
Group type: COMPARATOR
Intervention: Fasting only
Number of subjects: 293
Study 27476581 — intervention group
Group type: EXPERIMENTAL
Intervention: Camicinal (50 mg)
Number of subjects: 23
Study 27476581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 24530920 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fibre posts
Number of subjects: 54
Study 24530920 — intervention group
Group type: COMPARATOR
Intervention: Cast metal posts
Number of subjects: 54
Study 22750353 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐Communicating Adults Pain Checklist (NCAPC)
Number of subjects: 228
Study 22750353 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized group of participants (N=89)
Number of subjects: 228
Study 20067974 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg b.i.d.
Number of subjects: 258
Study 20067974 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride up to 6 mg q.d.
Number of subjects: 258
Study 18703934 — intervention group
Group type: COMPARATOR
Intervention: Lithium (starting dose: 400 mg/day)
Number of subjects: 300
Study 18703934 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (starting dose: 20 mg/kg/day)
Number of subjects: 300
Study 16319295 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic strategies including linkage and association studies, pharmacogenetics, and gene x environment interactions
Number of subjects: 0
Study 16319295 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroendocrine supplementation (thyroid and testosterone)
Number of subjects: 0
Study 16319295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine pathways
Number of subjects: 0
Study 15307437 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment (40 mg/kg) - first treatment
Number of subjects: 482
Study 15307437 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment (40 mg/kg) - second treatment
Number of subjects: 482
Study 15307437 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment (40 mg/kg) - side effects
Number of subjects: 482
Study 8621174 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid priming
Number of subjects: 38
Study 8621174 — intervention group
Group type: COMPARATOR
Intervention: Interferon only
Number of subjects: 38
Study 8466067 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine and opioids
Number of subjects: 153
Study 8466067 — intervention group
Group type: COMPARATOR
Intervention: Parenteral opioids
Number of subjects: 153
Study 2862814 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine 20 mg
Number of subjects: 12
Study 2862814 — intervention group
Group type: EXPERIMENTAL
Intervention: Orciprenaline 10 mg
Number of subjects: 12
Study 2862814 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol 10 mg
Number of subjects: 12